Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

Bäck TA, Jennbacken K, Hagberg Thulin M, Lindegren S, Jensen H, Olafsen T, Yazaki PJ, Palm S, Albertsson P, Damber JE, Wu AM, Welén K.

EJNMMI Res. 2020 Feb 11;10(1):10. doi: 10.1186/s13550-020-0600-z.

PMID:
32048062
2.

Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells.

Josefsson A, Larsson K, Freyhult E, Damber JE, Welén K.

Cancers (Basel). 2019 Dec 21;12(1). pii: E39. doi: 10.3390/cancers12010039.

3.

Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study.

Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P.

Acta Oncol. 2020 Jan;59(1):106-111. doi: 10.1080/0284186X.2019.1662084. Epub 2019 Sep 17.

PMID:
31526166
4.

AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer.

Josefsson A, Damber JE, Welén K.

Acta Oncol. 2019 Nov;58(11):1660-1664. doi: 10.1080/0284186X.2019.1637540. Epub 2019 Jul 9. No abstract available.

PMID:
31286815
5.

Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy.

Gunnarsson O, Schelin S, Brudin L, Carlsson S, Damber JE.

Scand J Urol. 2019 Apr - Jun;53(2-3):102-108. doi: 10.1080/21681805.2019.1600580. Epub 2019 Apr 16.

PMID:
30990112
6.

Androgen deprivation therapy for prostate cancer and risk of dementia.

Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J.

BJU Int. 2019 Jul;124(1):87-92. doi: 10.1111/bju.14666. Epub 2019 Feb 6.

7.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.

Scand J Urol. 2018 Oct - Dec;52(5-6):349-357. doi: 10.1080/21681805.2018.1522372. Epub 2019 Jan 9.

PMID:
30624128
8.

Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression.

Linder A, Hagberg Thulin M, Damber JE, Welén K.

Sci Rep. 2018 Nov 22;8(1):17259. doi: 10.1038/s41598-018-35332-4.

9.

Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden.

Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P.

Scand J Urol. 2018 Aug;52(4):277-284. doi: 10.1080/21681805.2018.1512650. Epub 2018 Oct 26.

PMID:
30362868
10.

Circulating tumor cells mirror bone metastatic phenotype in prostate cancer.

Josefsson A, Larsson K, Månsson M, Björkman J, Rohlova E, Åhs D, Brisby H, Damber JE, Welén K.

Oncotarget. 2018 Jun 29;9(50):29403-29413. doi: 10.18632/oncotarget.25634. eCollection 2018 Jun 29.

11.

A stage-dependent link between metabolic syndrome components and incident prostate cancer.

Hammarsten J, Damber JE, Haghsheno MA, Mellström D, Peeker R.

Nat Rev Urol. 2018 May;15(5):321-333. doi: 10.1038/nrurol.2018.8. Epub 2018 Feb 13. Review.

PMID:
29434372
12.

Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.

Jellvert Å, Åhs D, Olausson J, Franck Lissbrant I, Damber JE, Welén K.

Acta Oncol. 2018 Jul;57(7):895-901. doi: 10.1080/0284186X.2017.1423178. Epub 2018 Jan 4.

PMID:
29299975
13.

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, Widmark A, Thellenberg-Karlsson C, Budäus L, Steuber T, Eichenauer T, Wollmer P, Edenbrandt L, Trägårdh E, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):540-546. doi: 10.1016/j.euf.2016.02.013. Epub 2016 Mar 9.

PMID:
28723520
14.

Corrigendum re: "Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial" [Eur Urol 2015;68:216-25].

Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderäng U, Thorsteinsdottir T, Lagerkvist M, Damber JE, Bjartell A, Hugosson J, Wiklund P, Steineck G; LAPPRO steering committee.

Eur Urol. 2017 Sep;72(3):e81-e82. doi: 10.1016/j.eururo.2017.05.022. Epub 2017 May 25. No abstract available.

PMID:
28552613
15.

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

J Clin Oncol. 2017 May 1;35(13):1430-1436. doi: 10.1200/JCO.2016.69.5304. Epub 2017 Mar 13.

16.

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.

Josefsson A, Linder A, Flondell Site D, Canesin G, Stiehm A, Anand A, Bjartell A, Damber JE, Welén K.

Prostate. 2017 Jun;77(8):849-858. doi: 10.1002/pros.23325. Epub 2017 Mar 10.

PMID:
28295408
17.

Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.

Bentmar Holgersson M, Ruhayel Y, Karlsson M, Giwercman A, Bjartell A, Ohlsson C, Mellström D, Ljunggren Ö, Haghsheno MA, Damber JE, Lundberg Giwercman Y.

Cancer Causes Control. 2017 Mar;28(3):227-233. doi: 10.1007/s10552-017-0859-1. Epub 2017 Feb 7.

18.

Corrigendum re: "Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial" [Eur Urol 2016;70:566-73].

Bergdahl AG, Wilderäng U, Aus G, Carlsson S, Damber JE, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J.

Eur Urol. 2017 Feb;71(2):e81. doi: 10.1016/j.eururo.2016.09.014. Epub 2016 Sep 20. No abstract available.

PMID:
27663047
19.

Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort.

Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, Akre O.

Scand J Urol. 2016 Aug;50(4):255-9. doi: 10.1080/21681805.2016.1183226. Epub 2016 May 18.

PMID:
27192553
20.
21.

Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.

Fosså SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, Hoyer M, Widmark A; The Scandinavian Prostate Cancer Group-7 Investigators.

Eur Urol. 2016 Oct;70(4):684-691. doi: 10.1016/j.eururo.2016.03.021. Epub 2016 Mar 26.

PMID:
27025586
22.

Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

Grenabo Bergdahl A, Wilderäng U, Aus G, Carlsson S, Damber JE, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J.

Eur Urol. 2016 Oct;70(4):566-573. doi: 10.1016/j.eururo.2015.12.006. Epub 2015 Dec 24. Erratum in: Eur Urol. 2017 Feb;71(2):e81.

23.

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.

Magnusson LU, Hagberg Thulin M, Plas P, Olsson A, Damber JE, Welén K.

Prostate. 2016 Mar;76(4):383-93. doi: 10.1002/pros.23133. Epub 2015 Dec 10.

PMID:
26660725
24.

Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.

Hagberg Thulin M, Nilsson ME, Thulin P, Céraline J, Ohlsson C, Damber JE, Welén K.

Mol Cell Endocrinol. 2016 Feb 15;422:182-191. doi: 10.1016/j.mce.2015.11.013. Epub 2015 Nov 14.

25.

Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Damber JE.

Eur Urol. 2015 Dec;68(6):1102. doi: 10.1016/j.eururo.2015.08.051. No abstract available.

PMID:
26545574
26.

Insulin-like growth factor I and risk of incident cancer in elderly men - results from MrOS (Osteoporotic Fractures in Men) in Sweden.

Carlzon D, Svensson J, Petzold M, Karlsson MK, Ljunggren Ö, Haghsheno MA, Damber JE, Mellström D, Ohlsson C.

Clin Endocrinol (Oxf). 2016 May;84(5):764-70. doi: 10.1111/cen.12962. Epub 2015 Nov 19.

PMID:
26440042
27.

Dashboard report on performance on select quality indicators to cancer care providers.

Stattin P, Sandin F, Sandbäck T, Damber JE, Franck Lissbrant I, Robinson D, Bratt O, Lambe M.

Scand J Urol. 2016;50(1):21-8. doi: 10.3109/21681805.2015.1063083. Epub 2015 Jul 10.

PMID:
26162012
28.

[Go for MRI in the diagnosis of prostate cancer].

Bratt O, Ahlgren G, Andrén O, Blomqvist L, Carlsson S, Damber JE, Hugosson J, Jäderling F, Karlsson CT, Robinson D.

Lakartidningen. 2015 Apr 20;112. pii: DFZ3. Swedish. No abstract available.

29.

Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial.

Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderäng U, Thorsteinsdottir T, Lagerkvist M, Damber JE, Bjartell A, Hugosson J, Wiklund P, Steineck G; LAPPRO steering committee.

Eur Urol. 2015 Aug;68(2):216-25. doi: 10.1016/j.eururo.2015.02.029. Epub 2015 Mar 12.

30.

[Prostate cancer--new guidelines and the first care program].

Bratt O, Damber JE, Aldehag A, Brändström H.

Lakartidningen. 2015 Jan 27;112. pii: C6XC. Review. Swedish.

31.

Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.

Lennernäs B, Majumder K, Damber JE, Albertsson P, Holmberg E, Brandberg Y, Isacsson U, Ljung G, Damm O, Nilsson S.

Acta Oncol. 2015 Jun;54(6):875-81. doi: 10.3109/0284186X.2014.974827. Epub 2014 Nov 2.

PMID:
25362844
32.

Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement.

Haghsheno MA, Mellström D, Peeker R, Hammarsten J, Lorentzon M, Sundh V, Karlsson M, Ohlsson C, Damber JE.

Scand J Urol. 2015 Apr;49(2):155-61. doi: 10.3109/21681805.2014.936495. Epub 2014 Sep 25.

PMID:
25253423
33.

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).

Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle Ö, Pili R, Morris MJ.

Urol Oncol. 2014 Nov;32(8):1308-16. doi: 10.1016/j.urolonc.2014.08.006. Epub 2014 Sep 16.

34.

[Swedish medical research does not need more control].

Andersén P, Bäckström T, Dahlquist G, Damber JE, Engström-Laurent A, Gustafson Y, Hjemdahl P, Korsgren O, Olsson H, Wiberg M, Widmark A.

Lakartidningen. 2014 May 27-Jun 10;111(22-23):980-1. Swedish. No abstract available.

35.

Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.

Hagberg Thulin M, Jennbacken K, Damber JE, Welén K.

Clin Exp Metastasis. 2014 Mar;31(3):269-83. doi: 10.1007/s10585-013-9626-1. Epub 2013 Dec 1.

36.

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.

Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R.

Clin Cancer Res. 2013 Dec 15;19(24):6891-901. doi: 10.1158/1078-0432.CCR-13-1581. Epub 2013 Nov 19.

37.

Mechanisms of action of tasquinimod on the tumour microenvironment.

Raymond E, Dalgleish A, Damber JE, Smith M, Pili R.

Cancer Chemother Pharmacol. 2014 Jan;73(1):1-8. doi: 10.1007/s00280-013-2321-8. Epub 2013 Oct 27. Review.

38.

Interobserver variability in the pathological assessment of radical prostatectomy specimens: findings of the Laparoscopic Prostatectomy Robot Open (LAPPRO) study.

Persson J, Wilderäng U, Jiborn T, Wiklund PN, Damber JE, Hugosson J, Steineck G, Haglind E, Bjartell A.

Scand J Urol. 2014 Apr;48(2):160-7. doi: 10.3109/21681805.2013.820788. Epub 2013 Aug 1.

PMID:
23906418
39.

Low 25-OH vitamin D is associated with benign prostatic hyperplasia.

Haghsheno MA, Mellström D, Behre CJ, Damber JE, Johansson H, Karlsson M, Lorentzon M, Peeker R, Barret-Connor E, Waern E, Sundh V, Ohlsson C, Hammarsten J.

J Urol. 2013 Aug;190(2):608-14. doi: 10.1016/j.juro.2013.01.104. Epub 2013 Feb 8.

PMID:
23399651
40.

Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy.

Kaboteh R, Damber JE, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Edenbrandt L.

EJNMMI Res. 2013 Feb 6;3(1):9. doi: 10.1186/2191-219X-3-9.

41.

Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.

Nordin A, Wang W, Welén K, Damber JE.

Prostate. 2013 May;73(6):657-67. doi: 10.1002/pros.22607. Epub 2012 Nov 5.

PMID:
23129424
42.

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, van der Meulen E, Persson BE.

Urology. 2012 Jul;80(1):174-80. doi: 10.1016/j.urology.2012.01.092.

PMID:
22748873
43.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.

44.

Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).

Jennbacken K, Welén K, Olsson A, Axelsson B, Törngren M, Damber JE, Leanderson T.

Prostate. 2012 Jun 1;72(8):913-24. doi: 10.1002/pros.21495. Epub 2011 Oct 5.

PMID:
22287276
45.

Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2.

Tomić TT, Gustavsson H, Wang W, Jennbacken K, Welén K, Damber JE.

Prostate. 2012 May 15;72(7):705-12. doi: 10.1002/pros.21472. Epub 2011 Aug 1.

PMID:
21809353
46.

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP.

Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.

PMID:
21627403
47.

Prostate diseases--role of sex steroids and their inhibitors.

Welén K, Damber JE.

Best Pract Res Clin Endocrinol Metab. 2011 Apr;25(2):355-67. doi: 10.1016/j.beem.2010.09.008.

PMID:
21397203
48.

30 minutes high energy transurethral microwave thermotherapy (30 minutes TUMT) for the treatment of chronic urinary retention in patients with ASA II-III-IV.

Dicuio M, Vesely S, Knutson T, Damber JE, Cuzzocrea DE, Dahlstrand C.

Arch Ital Urol Androl. 2010 Sep;82(3):149-54.

PMID:
21121432
49.

LAPPRO: a prospective multicentre comparative study of robot-assisted laparoscopic and retropubic radical prostatectomy for prostate cancer.

Thorsteinsdottir T, Stranne J, Carlsson S, Anderberg B, Björholt I, Damber JE, Hugosson J, Wilderäng U, Wiklund P, Steineck G, Haglind E.

Scand J Urol Nephrol. 2011 Mar;45(2):102-12. doi: 10.3109/00365599.2010.532506. Epub 2010 Nov 29.

PMID:
21114378
50.

O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.

Premaratne P, Welén K, Damber JE, Hansson GC, Bäckström M.

Tumour Biol. 2011 Feb;32(1):203-13. doi: 10.1007/s13277-010-0114-9. Epub 2010 Sep 26.

PMID:
20872286

Supplemental Content

Loading ...
Support Center